Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)

CAPS Rating: 2 out of 5

Recs

3
Player Avatar zzlangerhans (99.78) Submitted: 2/1/2011 4:59:12 PM : Underperform Start Price: $13.30 AEGR Score: +14.12

Aegerion's share price has been flying all over the map for the last month. I'll re-enter my down thumb here.The company's only drug in clinical trials is lomitapide, which is in a phase III trial for homozygous familial hypercholesterolemia. Isis hasn't generated much excitement for this niche market with mipomersen, and I don't expect recent upward momentum in Aegerion's share price to be sustained. Ironically, the share price is almost as high as the IPO target of 14 which the company climbed down from just two months ago.

Featured Broker Partners


Advertisement